Hwalek Ann, Rosenheck Justin P, Whitson Bryan A
Division of Cardiac Surgery, Columbus, Department of Surgery, The Ohio State University Wexner Medical Center, OH, USA.
Division of Pulmonary, Critical Care & Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
J Thorac Dis. 2021 Nov;13(11):6708-6716. doi: 10.21037/jtd-2021-20.
From its identification as a distinct disease entity, understanding and management of pulmonary hypertension has continuously evolved. Diagnostic and therapeutic interventions have greatly improved the prognostic implications of this devastating disease, previously rapidly and uniformly fatal to one chronically managed by multi-disciplinary teams. Improved diagnostic algorithms and active research into biochemical signatures of pulmonary hypertension (PH) have led to earlier diagnosis of PH. Medical therapy has moved from upfront use of continuous intravenous prostaglandins to administration of combinations of oral medications targeting multiple pathways underlying this disease process. In addition to improved medical therapies, recently introduced interventions such as pulmonary endarterectomy and pulmonary artery balloon angioplasty for chronic thromboembolic pulmonary hypertension (CTEPH) give patients an increasing array of treatment options. Despite these many advances, lung transplantation remains the definitive treatment for patients with disease refractory to or progressing on best medical therapy. As our understanding of medical therapy has advanced, so to have best practices for lung transplantation. Recipient selection and approach to organ transplantation techniques have continuously evolved. Mechanical circulatory support has become increasingly employed to bridge patients through lung transplantation in the immediate post transplantation recovery. In this review, we give a history of lung transplantation for PH, an overview of PH, discuss current best practices and look to the future for insights into the care of these patients.
从被确认为一种独特的疾病实体以来,对肺动脉高压的认识和管理一直在不断发展。诊断和治疗干预极大地改善了这种毁灭性疾病的预后,这种疾病以前迅速且无一例外地致命,现在由多学科团队进行长期管理。改进的诊断算法以及对肺动脉高压(PH)生化特征的积极研究已导致PH的早期诊断。药物治疗已从最初使用持续静脉注射前列腺素转变为使用针对该疾病过程多个潜在途径的口服药物组合。除了改进的药物治疗外,最近引入的干预措施,如用于慢性血栓栓塞性肺动脉高压(CTEPH)的肺动脉内膜切除术和肺动脉球囊血管成形术,为患者提供了越来越多的治疗选择。尽管取得了这些诸多进展,但肺移植仍然是对最佳药物治疗无效或病情进展的患者的最终治疗方法。随着我们对药物治疗的理解不断进步,肺移植的最佳实践也是如此。受体选择和器官移植技术的方法一直在不断发展。机械循环支持越来越多地被用于在移植后立即恢复期间帮助患者度过肺移植过程。在这篇综述中,我们讲述了PH肺移植的历史,概述了PH,讨论了当前的最佳实践,并展望未来,以期深入了解这些患者的护理。